EGFR and breast carcinoma: Interestingly, it was reported that a dual HER1/HER2 inhibitor lapatinib significantly reduced the proportion of CD44+/CD24- breast cancer cells, putative stem cells, and also reduced the number of mammosphere-forming activity associated with a significant antitumor activity in HER2-positive breast cancers in the neoadjuvant setting [13].